Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein.

Tang A, Chen Z, Cox KS, Su HP, Callahan C, Fridman A, Zhang L, Patel SB, Cejas PJ, Swoyer R, Touch S, Citron MP, Govindarajan D, Luo B, Eddins M, Reid JC, Soisson SM, Galli J, Wang D, Wen Z, Heidecker GJ, Casimiro DR, DiStefano DJ, Vora KA.

Nat Commun. 2019 Sep 12;10(1):4153. doi: 10.1038/s41467-019-12137-1.

PMID:
31515478
2.

Immune response and reactogenicity of an unadjuvanted intradermally delivered human papillomavirus vaccine using a first generation Nanopatch™ in rhesus macaques: An exploratory, pre-clinical feasibility assessment.

Meyer BK, Kendall MAF, Williams DM, Bett AJ, Dubey S, Gentzel RC, Casimiro D, Forster A, Corbett H, Crichton M, Baker SB, Evans RK, Bhambhani A.

Vaccine X. 2019 Jun 20;2:100030. doi: 10.1016/j.jvacx.2019.100030. eCollection 2019 Aug 9.

3.

Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes.

Li L, Meng W, Horton M, DiStefano DR, Thoryk EA, Pfaff JM, Wang Q, Salazar GT, Barnes T, Doranz BJ, Bett AJ, Casimiro DR, Vora KA, An Z, Zhang N.

PLoS Pathog. 2019 Jun 6;15(6):e1007716. doi: 10.1371/journal.ppat.1007716. eCollection 2019 Jun.

4.

Progress and challenges in TB vaccine development.

Voss G, Casimiro D, Neyrolles O, Williams A, Kaufmann SHE, McShane H, Hatherill M, Fletcher HA.

F1000Res. 2018 Feb 16;7:199. doi: 10.12688/f1000research.13588.1. eCollection 2018. Review.

5.

Functionally inactivated dominant viral antigens of human cytomegalovirus delivered in replication incompetent adenovirus type 6 vectors as vaccine candidates.

Tang A, Freed DC, Li F, Meschino S, Prokop M, Bett A, Casimiro D, Wang D, Fu TM.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2763-2771. doi: 10.1080/21645515.2017.1308988. Epub 2017 May 11.

6.

Co-Administration of Lipid Nanoparticles and Sub-Unit Vaccine Antigens Is Required for Increase in Antigen-Specific Immune Responses in Mice.

Thoryk EA, Swaminathan G, Meschino S, Cox KS, Gindy M, Casimiro DR, Bett AJ.

Vaccines (Basel). 2016 Dec 6;4(4). pii: E47.

7.

IMPre: An Accurate and Efficient Software for Prediction of T- and B-Cell Receptor Germline Genes and Alleles from Rearranged Repertoire Data.

Zhang W, Wang IM, Wang C, Lin L, Chai X, Wu J, Bett AJ, Dhanasekaran G, Casimiro DR, Liu X.

Front Immunol. 2016 Nov 4;7:457. eCollection 2016.

8.

A replication-defective human cytomegalovirus vaccine for prevention of congenital infection.

Wang D, Freed DC, He X, Li F, Tang A, Cox KS, Dubey SA, Cole S, Medi MB, Liu Y, Xu J, Zhang ZQ, Finnefrock AC, Song L, Espeseth AS, Shiver JW, Casimiro DR, Fu TM.

Sci Transl Med. 2016 Oct 26;8(362):362ra145.

PMID:
27797961
9.

A Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human Primates.

Swaminathan G, Thoryk EA, Cox KS, Smith JS, Wolf JJ, Gindy ME, Casimiro DR, Bett AJ.

Sci Rep. 2016 Oct 5;6:34215. doi: 10.1038/srep34215.

10.

Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F Glycoprotein.

Chen Z, Zhang L, Tang A, Callahan C, Pristatsky P, Swoyer R, Cejas P, Nahas D, Galli J, Cosmi S, DiStefano D, Hoang VM, Bett A, Casimiro D, Vora KA.

PLoS One. 2016 Jun 3;11(6):e0156798. doi: 10.1371/journal.pone.0156798. eCollection 2016.

11.

Characterization of N-glycosylation profiles from mammalian and insect cell derived chikungunya VLP.

Lancaster C, Pristatsky P, Hoang VM, Casimiro DR, Schwartz RM, Rustandi R, Ha S.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 1;1032:218-223. doi: 10.1016/j.jchromb.2016.04.025. Epub 2016 Apr 21.

PMID:
27157808
12.

A Rapid and Improved Method to Generate Recombinant Dengue Virus Vaccine Candidates.

Govindarajan D, Guan L, Meschino S, Fridman A, Bagchi A, Pak I, ter Meulen J, Casimiro DR, Bett AJ.

PLoS One. 2016 Mar 23;11(3):e0152209. doi: 10.1371/journal.pone.0152209. eCollection 2016.

13.

Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination.

Fourati S, Cristescu R, Loboda A, Talla A, Filali A, Railkar R, Schaeffer AK, Favre D, Gagnon D, Peretz Y, Wang IM, Beals CR, Casimiro DR, Carayannopoulos LN, Sékaly RP.

Nat Commun. 2016 Jan 8;7:10369. doi: 10.1038/ncomms10369.

14.

Effector and Central Memory Poly-Functional CD4(+) and CD8(+) T Cells are Boosted upon ZOSTAVAX(®) Vaccination.

Sei JJ, Cox KS, Dubey SA, Antonello JM, Krah DL, Casimiro DR, Vora KA.

Front Immunol. 2015 Oct 29;6:553. doi: 10.3389/fimmu.2015.00553. eCollection 2015.

15.

A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens.

Swaminathan G, Thoryk EA, Cox KS, Meschino S, Dubey SA, Vora KA, Celano R, Gindy M, Casimiro DR, Bett AJ.

Vaccine. 2016 Jan 2;34(1):110-9. doi: 10.1016/j.vaccine.2015.10.132. Epub 2015 Nov 10.

PMID:
26555351
16.

Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures.

Cox KS, Tang A, Chen Z, Horton MS, Yan H, Wang XM, Dubey SA, DiStefano DJ, Ettenger A, Fong RH, Doranz BJ, Casimiro DR, Vora KA.

MAbs. 2016;8(1):129-40. doi: 10.1080/19420862.2015.1109757. Epub 2015 Oct 22.

17.

Preclinical and clinical development of a dengue recombinant subunit vaccine.

Manoff SB, George SL, Bett AJ, Yelmene ML, Dhanasekaran G, Eggemeyer L, Sausser ML, Dubey SA, Casimiro DR, Clements DE, Martyak T, Pai V, Parks DE, Coller BA.

Vaccine. 2015 Dec 10;33(50):7126-34. doi: 10.1016/j.vaccine.2015.09.101. Epub 2015 Oct 14. Review.

PMID:
26458804
18.

DNA vaccines targeting heavy chain C-terminal fragments of Clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge.

Scott VL, Villarreal DO, Hutnick NA, Walters JN, Ragwan E, Bdeir K, Yan J, Sardesai NY, Finnefrock AC, Casimiro DR, Weiner DB.

Hum Vaccin Immunother. 2015;11(8):1961-71. doi: 10.1080/21645515.2015.1066051.

19.

Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates.

Govindarajan D, Meschino S, Guan L, Clements DE, ter Meulen JH, Casimiro DR, Coller BA, Bett AJ.

Vaccine. 2015 Aug 7;33(33):4105-16. doi: 10.1016/j.vaccine.2015.06.067. Epub 2015 Jul 3.

PMID:
26144900
20.

Efficient generation of monoclonal antibodies from single rhesus macaque antibody secreting cells.

Meng W, Li L, Xiong W, Fan X, Deng H, Bett AJ, Chen Z, Tang A, Cox KS, Joyce JG, Freed DC, Thoryk E, Fu TM, Casimiro DR, Zhang N, A Vora K, An Z.

MAbs. 2015;7(4):707-18. doi: 10.1080/19420862.2015.1051440.

21.

Development and application of a reversed-phase high-performance liquid chromatographic method for quantitation and characterization of a Chikungunya virus-like particle vaccine.

Shytuhina A, Pristatsky P, He J, Casimiro DR, Schwartz RM, Hoang VM, Ha S.

J Chromatogr A. 2014 Oct 17;1364:192-7. doi: 10.1016/j.chroma.2014.05.087. Epub 2014 Jun 19.

22.
23.

Enhanced production of Chikungunya virus-like particles using a high-pH adapted spodoptera frugiperda insect cell line.

Wagner JM, Pajerowski JD, Daniels CL, McHugh PM, Flynn JA, Balliet JW, Casimiro DR, Subramanian S.

PLoS One. 2014 Apr 8;9(4):e94401. doi: 10.1371/journal.pone.0094401. eCollection 2014.

24.

Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.

Freed DC, Tang Q, Tang A, Li F, He X, Huang Z, Meng W, Xia L, Finnefrock AC, Durr E, Espeseth AS, Casimiro DR, Zhang N, Shiver JW, Wang D, An Z, Fu TM.

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4997-5005. doi: 10.1073/pnas.1316517110. Epub 2013 Dec 2.

25.

Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.

Awasthi S, Balliet JW, Flynn JA, Lubinski JM, Shaw CE, DiStefano DJ, Cai M, Brown M, Smith JF, Kowalski R, Swoyer R, Galli J, Copeland V, Rios S, Davidson RC, Salnikova M, Kingsley S, Bryan J, Casimiro DR, Friedman HM.

J Virol. 2014 Feb;88(4):2000-10. doi: 10.1128/JVI.03163-13. Epub 2013 Nov 27.

26.

Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques.

DiStefano D, Antonello JM, Bett AJ, Medi MB, Casimiro DR, ter Meulen J.

Vaccine. 2013 Oct 1;31(42):4888-93. doi: 10.1016/j.vaccine.2013.07.034. Epub 2013 Aug 11.

PMID:
23941913
27.

Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection.

Janes H, Friedrich DP, Krambrink A, Smith RJ, Kallas EG, Horton H, Casimiro DR, Carrington M, Geraghty DE, Gilbert PB, McElrath MJ, Frahm N.

J Infect Dis. 2013 Oct 15;208(8):1231-9. doi: 10.1093/infdis/jit322. Epub 2013 Jul 21.

28.

HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.

Hertz T, Ahmed H, Friedrich DP, Casimiro DR, Self SG, Corey L, McElrath MJ, Buchbinder S, Horton H, Frahm N, Robertson MN, Graham BS, Gilbert P.

PLoS Pathog. 2013;9(6):e1003404. doi: 10.1371/journal.ppat.1003404. Epub 2013 Jun 20.

29.

An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform.

Fridman A, Finnefrock AC, Peruzzi D, Pak I, La Monica N, Bagchi A, Casimiro DR, Ciliberto G, Aurisicchio L.

Oncoimmunology. 2012 Nov 1;1(8):1258-1270.

30.

Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus.

Fu TM, Wang D, Freed DC, Tang A, Li F, He X, Cole S, Dubey S, Finnefrock AC, ter Meulen J, Shiver JW, Casimiro DR.

Vaccine. 2012 Dec 14;30(52):7469-74. doi: 10.1016/j.vaccine.2012.10.053. Epub 2012 Oct 26.

PMID:
23107592
31.

A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge.

Reynolds MR, Weiler AM, Piaskowski SM, Piatak M Jr, Robertson HT, Allison DB, Bett AJ, Casimiro DR, Shiver JW, Wilson NA, Lifson JD, Koff WC, Watkins DI.

Vaccine. 2012 Jun 22;30(30):4465-75. doi: 10.1016/j.vaccine.2012.04.082. Epub 2012 May 6.

32.

The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes.

Perreau M, Welles HC, Pellaton C, Gjoksi B, Potin L, Martin R, Harari A, Bett A, Casimiro D, Gall J, Barouch DH, Kremer EJ, Pantaleo G.

J Virol. 2012 Jun;86(11):6279-85. doi: 10.1128/JVI.00123-12. Epub 2012 Apr 4.

33.

An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge.

Hutnick NA, Myles DJ, Hirao L, Scott VL, Ferraro B, Khan AS, Lewis MG, Miller CJ, Bett AJ, Casimiro D, Sardesai NY, Kim JJ, Shiver J, Weiner DB.

Vaccine. 2012 May 2;30(21):3202-8. doi: 10.1016/j.vaccine.2012.02.069. Epub 2012 Mar 8.

PMID:
22406458
34.

Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.

Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, Cai M, Lubinski JM, Barrett SM, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM.

J Virol. 2012 Apr;86(8):4586-98. doi: 10.1128/JVI.07203-11. Epub 2012 Feb 8.

35.

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.

Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, Casimiro DR, Duerr A, Robertson MN, Buchbinder SP, Huang Y, Spies GA, De Rosa SC, McElrath MJ.

J Clin Invest. 2012 Jan;122(1):359-67. doi: 10.1172/JCI60202. Epub 2011 Dec 27.

36.

Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.

Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, DiPasquale J, DeSilva V, Fritts L, Bett AJ, Casimiro DR, Shiver JW, Robert-Guroff M, Robertson MN, McChesney MB, Gilbert PB, Miller CJ.

J Virol. 2012 Feb;86(4):2239-50. doi: 10.1128/JVI.06175-11. Epub 2011 Dec 7.

37.

Evaluating functional antibodies in rhesus monkeys immunized with hepatitis B virus surface antigen vaccine with novel adjuvant formulations.

Freed DC, Towne VM, Casimiro DR, Zhao Q, Fu TM.

Vaccine. 2011 Nov 21;29(50):9385-90. doi: 10.1016/j.vaccine.2011.09.122. Epub 2011 Oct 11.

PMID:
22001120
38.

Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection.

Wang D, Li F, Freed DC, Finnefrock AC, Tang A, Grimes SN, Casimiro DR, Fu TM.

Vaccine. 2011 Nov 8;29(48):9075-80. doi: 10.1016/j.vaccine.2011.09.056. Epub 2011 Sep 22.

PMID:
21945962
39.

A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines.

Tang A, Li F, Freed DC, Finnefrock AC, Casimiro DR, Wang D, Fu TM.

Vaccine. 2011 Oct 26;29(46):8350-6. doi: 10.1016/j.vaccine.2011.08.086. Epub 2011 Aug 31.

PMID:
21888937
40.

Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.

Awasthi S, Lubinski JM, Shaw CE, Barrett SM, Cai M, Wang F, Betts M, Kingsley S, Distefano DJ, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM.

J Virol. 2011 Oct;85(20):10472-86. doi: 10.1128/JVI.00849-11. Epub 2011 Aug 3.

41.

Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.

Li F, Finnefrock AC, Dubey SA, Korber BT, Szinger J, Cole S, McElrath MJ, Shiver JW, Casimiro DR, Corey L, Self SG.

PLoS One. 2011;6(6):e20479. doi: 10.1371/journal.pone.0020479. Epub 2011 Jun 10.

42.

Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.

Kandimalla ER, Struthers M, Bett AJ, Wisniewski T, Dubey SA, Jiang W, Precopio M, Sun Z, Wang H, Lan T, Agrawal S, Casimiro DR.

Cell Immunol. 2011;270(2):126-34. doi: 10.1016/j.cellimm.2011.03.027. Epub 2011 Apr 22.

PMID:
21570062
43.

Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.

Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR, McElrath MJ.

PLoS One. 2011 Apr 13;6(4):e18526. doi: 10.1371/journal.pone.0018526.

44.

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.

Rolland M, Tovanabutra S, deCamp AC, Frahm N, Gilbert PB, Sanders-Buell E, Heath L, Magaret CA, Bose M, Bradfield A, O'Sullivan A, Crossler J, Jones T, Nau M, Wong K, Zhao H, Raugi DN, Sorensen S, Stoddard JN, Maust BS, Deng W, Hural J, Dubey S, Michael NL, Shiver J, Corey L, Li F, Self SG, Kim J, Buchbinder S, Casimiro DR, Robertson MN, Duerr A, McElrath MJ, McCutchan FE, Mullins JI.

Nat Med. 2011 Mar;17(3):366-71. doi: 10.1038/nm.2316. Epub 2011 Feb 27.

45.

Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.

Fellay J, Frahm N, Shianna KV, Cirulli ET, Casimiro DR, Robertson MN, Haynes BF, Geraghty DE, McElrath MJ, Goldstein DB; National Institute of Allergy and Infectious Diseases Center for HIV/AIDS Vaccine Immunology; NIAID HIV Vaccine Trials Network.

J Infect Dis. 2011 Mar 15;203(6):773-9. doi: 10.1093/infdis/jiq125. Epub 2011 Jan 28.

46.

Vaccination with Ad5 vectors expands Ad5-specific CD8 T cells without altering memory phenotype or functionality.

Hutnick NA, Carnathan DG, Dubey SA, Cox KS, Kierstead L, Makadonas G, Ratcliffe SJ, Lasaro MO, Robertson MN, Casimiro DR, Ertl HC, Betts MR.

PLoS One. 2010 Dec 22;5(12):e14385. doi: 10.1371/journal.pone.0014385.

47.

Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective.

Staprans SI, Feinberg MB, Shiver JW, Casimiro DR.

Curr Opin HIV AIDS. 2010 Sep;5(5):377-85. doi: 10.1097/COH.0b013e32833d2e19. Review.

PMID:
20978377
48.

Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.

Bett AJ, Dubey SA, Mehrotra DV, Guan L, Long R, Anderson K, Collins K, Gaunt C, Fernandez R, Cole S, Meschino S, Tang A, Sun X, Gurunathan S, Tartaglia J, Robertson MN, Shiver JW, Casimiro DR.

Vaccine. 2010 Nov 23;28(50):7881-9. doi: 10.1016/j.vaccine.2010.09.079. Epub 2010 Oct 23.

PMID:
20937317
49.

Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.

Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV, Self S, Turner K, Sanchez J, Pitisuttithum P, Duerr A, Dubey S, Kierstead L, Casimiro D, Hammer SM; for the Merck V520-018/HIV Vaccine Trials Network 050 Study Team.

AIDS Res Hum Retroviruses. 2010 Nov 23. [Epub ahead of print]

50.

AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.

Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, Pollard R, Battaglia C, Robertson M, Mehrotra D, Casimiro D, Cox K, Schock B; AIDS Clinical Trials Group 5197 Study Team.

J Infect Dis. 2010 Sep 1;202(5):705-16. doi: 10.1086/655468.

Supplemental Content

Loading ...
Support Center